Text Size

Serial Changes of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Levels in Patients With Acute Respiratory Distress Syndrome

This study has been completed.
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00557414
First received: November 12, 2007
Last updated: May 8, 2008
Last verified: May 2008
History of Changes
  Purpose

The purpose of this study is to determine the impact of the serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) on etiology and prognosis of acute respiratory distress syndrome (ARDS)


Condition
Acute Respiratory Distress Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Serial Changes of sTREM-1 Levels in Patients With Acute Respiratory Distress Syndrome

Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • all cause mortality [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  • Septic or non-septic etiology [ Time Frame: At enrollment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • CRP, lactate, WBC count, APACHE II score, LIS, SOFA score [ Time Frame: At enrollment ] [ Designated as safety issue: No ]
  • IL-1 beta, IL-8, TNF-alpha [ Time Frame: serial follow up at Day 1, 3, 5, 7, 14 ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

serum


Enrollment: 63
Study Start Date: October 2007
Study Completion Date: March 2008
Detailed Description:

The triggering receptor expressed on myeloid cells-1 (TREM-1), a member of the immunoglobulin superfamily, is upregulated on phagocytic cells in the presence of bacteria or fungi infection and weakly expressed in samples from patients with noninfectious inflammatory disorders. In addition, TREM-1 is shed from the membrane of activated phagocytes and can be found in a soluble form (sTREM-1) in body fluids. The level and serial change of a serum sTREM-1 from cirtical ill patients has been shown to be a good diagnostic and prognostic indicator of ventilation associated pneumonia (VAP) and severe sepsis.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients admitted into ICU of a medical center in Taiwan

Criteria

Inclusion Criteria:

  • Fulfill clinical diagnosis of ARDS
  • Require mechanical ventilation support

Exclusion Criteria:

  • Pregnant
  • Immunocompromised
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00557414

Locations
Taiwan
National Taiwan University Hospital
Taipei, Taiwan, 100
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Chao-Chi Ho Department of Internal Medicine and Emergency Medicine, National Taiwan University Hospital
  More Information

No publications provided

Responsible Party: Chao-Chi Ho, National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT00557414     History of Changes
Other Study ID Numbers: 200709060R
Study First Received: November 12, 2007
Last Updated: May 8, 2008
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
acute respiratory distress syndrome
soluble triggering receptor expressed on myeloid cells-1
prognosis

Additional relevant MeSH terms:
Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome, Adult
Acute Lung Injury
Lung Diseases
Respiratory Tract Diseases
 Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Lung Injury

ClinicalTrials.gov processed this record on May 23, 2013